HealthCap invests in Neobiomics to support continued growth in neonatal care
HealthCap invests in Neobiomics to support continued growth in neonatal care
Stockholm, Sweden – 20 May 2026. Neobiomics AB, a Swedish life science company focused on improving outcomes for preterm infants through evidence-based nutritional products, today announced an investment led by HealthCap, one of Europe’s leading life science venture capital investors. In conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director: Mårten Steen, Managing Partner at HealthCap.
The investment will support Neobiomics’ continued commercial expansion, international growth, and further development of its portfolio within neonatal and pediatric health.
Neobiomics is focused on developing and commercializing clinically documented nutritional products for vulnerable patient populations, with a particular focus on preterm infants. The company’s lead product, ProPrems®, is used in neonatal intensive care settings across Europe and the Middle East. In 2024, Neobiomics expanded its portfolio with the launch of NeoMega36®, further strengthening its position within evidence-based neonatal nutrition.
“HealthCap’s investment is a strong validation of the clinical relevance and long-term potential of Neobiomics. We have built the company with a clear mission: to translate clinical evidence into products designed specifically for the most vulnerable patients, where decisions have lifelong consequences. With HealthCap onboard, we are well positioned to accelerate our international growth and continue building a leading company within neonatology” said Stefan Johansson, Co-founder and Chairman of Neobiomics.
“We are very pleased to welcome HealthCap as an investor and long-term partner,” said Emma Höglund, CEO of Neobiomics. “HealthCap brings deep life science expertise, a strong international network, and extensive experience in building global life science companies. This investment is an important milestone for Neobiomics and supports our ambition to bring evidence-based neonatal solutions to more infants worldwide.”
“The unmet medical need in neonatal care remains significant – outcomes for the most vulnerable newborns depend on earlier, more accurate intervention. Neobiomics is addressing this gap with a compelling and differentiated portfolio, backed by strong clinical evidence and a proven commercial presence. We are excited to support the company as they move into their next phase of growth. ,” said Mårten Steen, Managing Partner at HealthCap.
The transaction closed on 20 May 2026.
About HealthCap
HealthCap is a European venture capital firm investing globally in life sciences and has raised eight funds since 1996. HealthCap has backed and built more than 130 companies, taken 48 companies public, and completed numerous trade sales. The investment strategy focuses on diseases with a high unmet medical need and breakthrough therapies that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.
About Neobiomics
Neobiomics is dedicated to solving the unmet needs in neonatology, addressing major challenges for preterm infants. Founded in 2016, Neobiomics is a fast-growing company located at the Karolinska Institutet Science Park in Stockholm. As of today, Neobiomics has two products available on the market. ProPrems®, a high-quality and well-documented probiotic blend and NeoMega36®, a tailor-made oil enriched with arachidonic acid and DHA, recently launched as a Food for Special Medical Purposes (FSMP). Since 2023, Neobiomics has a wholesale dealer authorisation, enabling future distribution of pharmaceutical products for pediatric and neonatal hospital care. In 2025, Neobiomics was recognized with the Export Rising Star award by Swecare and selected as a DI Gasell company in recognition of its sustainable growth.
For further information, please contact:
Emma Höglund, CEO +46 703 030 138
Stefan Johansson, Co-Founder and Chairman of the Board +46 703 49 59 47
